Mineralys Therapeutics Announces Positive Results from Hypertension Trials
Portfolio | Mar 10, 2025 | Ysios Capital
Mineralys Therapeutics has announced positive topline results from its pivotal trials, Launch-HTN and Advance-HTN, evaluating Lorundrostat for the treatment of uncontrolled or resistant hypertension. These trials have demonstrated significant efficacy and opened potential pathways for advancing the treatment options for hypertension, a prevalent condition with limited current solutions. The announcement marks a significant milestone for Mineralys, a portfolio company of Ysios Capital, as it progresses towards potential market approval and commercialization. These results could have major implications for the ongoing management and treatment strategies of hypertension.
Sectors
- Biopharmaceutical
- Healthcare
Geography
- United States – The pivotal trials for Lorundrostat took place in the United States, reflecting its significant presence in the U.S. healthcare and biopharmaceutical markets.
Industry
- Biopharmaceutical – Mineralys Therapeutics is involved in the biopharmaceutical sector, working on drug development for hypertension.
- Healthcare – The results of the trials are significant for the healthcare industry, particularly in addressing treatment gaps in hypertension management.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Mineralys Therapeutics | Target | Company | A biopharmaceutical company conducting pivotal trials for hypertension treatment. |
| Ysios Capital | Private Equity Firm | Company | A private equity firm with Mineralys as a part of its portfolio. |